AbbVie's blockbuster eye drug Restasis under threat as FDA approves Viatris' copycat

When AbbVie came up with its 2022 financial projections and shared them with investors early Wednesday, the company said it expects to retain U.S. exclusivity on blockbuster eye drug Restasis through the first half of the year. After the FDA approved the first generic to the drug that afternoon, those hopes may be dashed.